NRx Pharma Stock Jumps After FDA Signals Path To NDA For Ketamine Depression Drug
The FDA signals its willingness to review NRx Pharmaceuticals' NRX-100 NDA, boosting optimism around its depression treatment.
Open original sourceLoading market dashboard